We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
How marketing authorisation holders should inform MHRA of a signal or an ADR to a medicine.
The Medicines and Healthcare products Regulatory Agency (MHRA) offer a pre-submission service before applying for medicines Marketing Authorisations and clinical variations innovative medicines.
Guidance for submitting changes to labels and Patient Information Leaflets (PILs) as a self-certification.
How to renew marketing authorisations for products granted through different routes and at different times.
How we regulate in vitro diagnostic medical devices (IVDs) that are placed on the UK market.
Project Orbis is a programme to review and approve promising cancer drugs helping patients access treatments faster.
How we engage and involve patients and the public in our regulatory decision-making.
Information about the MHRA's duties and how you can report a non-compliant medical device.
Approach to MHRA’s assessment of applications for medicines that use alternative methods to replace animals in science
How to apply for a traditional herbal registration (THR) to market a herbal medicine in the UK.
How to join the phase I accreditation scheme.
How to submit your periodic safety update report report (PSUR) or periodic benefit risk evaluation report (PBRER)
Marketing Authorisation Holders should review their manufacturing processes to mitigate the risk of nitrosamine impurities being present.
Supporting guidance, publications and resources on the use of real-world data (RWD) and real-world evidence (RWE) in regulatory decision-making for medicines and medical devices in the UK.
Since, April 2024, the MHRA has been using Lorenz DocuBridge for eCTD management in product licence submissions. This change is part of the modernisation of the MHRA’s Legacy Systems and is one of the initial tools launched …
Guidance for health institutions that manufacture general medical devices under the Health Institution Exemption (HIE).
Guidance on good manufacturing practice and the use of radiopharmaceutical investigational medicinal products in clinical trials.
Information for clinicians and patients.
Supporting information to accompany the National Patient Safety Alert on patient hoists and slings NatPSA/2026/005/MHRA.
How to change the ownership from one marketing authorisation (MA) holder to another.
Do not include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).